UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 191

Sortiert nach

Pharmacological validation of TDO as a target for Parkinson’s disease

The FEBS journal, 2021-07, Vol.288 (14), p.4311-4331

2021

Volltextzugriff (PDF)

TTK Inhibitors as a Targeted Therapy for CTNNB1 ( β -catenin) Mutant Cancers

Molecular cancer therapeutics, 2017-11, Vol.16 (11), p.2609-2617

2017

Volltextzugriff (PDF)

Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use

PloS one, 2014-03, Vol.9 (3), p.e92146-e92146

2014

Volltextzugriff (PDF)

A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets

British journal of pharmacology, 2012-06, Vol.166 (3), p.858-876

2012

Volltextzugriff (PDF)

Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combination

Frontiers in oncology, 2024-08, Vol.14

2024

Volltextzugriff (PDF)

Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0

Frontiers in immunology, 2021-01, Vol.11, p.609490-609490

2021

Volltextzugriff (PDF)

Structural insights into human Arginase-1 pH dependence and its inhibition by the small molecule inhibitor CB-1158

Journal of structural biology. X, 2020-01, Vol.4, p.100014-100014, Article 100014

2020

Volltextzugriff (PDF)

Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines

Oncotarget, 2017-06, Vol.8 (24), p.38309-38325

2017

Volltextzugriff (PDF)

Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs

PloS one, 2015-05, Vol.10 (5), p.e0125021

2015

Volltextzugriff (PDF)

Optimisation of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors

Bioorganic & medicinal chemistry letters, 2011-02, Vol.21 (4), p.1084-1088

2011

Volltextzugriff (PDF)

An improved synthesis of 2-oxa-7-azaspiro[3,5]nonane and analogs as novel reagents in medicinal chemistry

Tetrahedron letters, 2011-06, Vol.52 (26), p.3266-3270

2011

Volltextzugriff (PDF)

Abstract 1480: Comparative cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1480-1480

2021

Volltextzugriff (PDF)

Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity

Journal of molecular biology, 2017-07, Vol.429 (14), p.2211-2230

2017

Volltextzugriff (PDF)

Abstract B065: TTK inhibitors as a targeted therapy for β-catenin mutant cancers

Molecular cancer therapeutics, 2018-01, Vol.17 (1_Supplement), p.B065-B065

2018

Volltextzugriff (PDF)

Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance

Journal of molecular biology, 2017-02, Vol.429 (4), p.574-586

2017

Volltextzugriff (PDF)

LCK inhibition downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinoma

Journal of hepatology, 2023-01, Vol.78 (1), p.142-152

2023

Volltextzugriff (PDF)

Abstract B060: Side-by-side comparison of small molecule IDO1 inhibitors in biochemical and cell-based assays and development of a IDO1 -expressing mouse model to evaluate target modulation

Molecular cancer therapeutics, 2019-12, Vol.18 (12_Supplement), p.B060-B060

2019

Volltextzugriff (PDF)

Preclinical evaluation of LCK as a novel therapeutic target in YAP-activated and FGFR2-altered cholangiocarcinoma

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.463-463

2022

Volltextzugriff (PDF)

Abstract 2158: Combining cell panel profiling and synthetic lethality data to efficiently screen for synergistic combinations

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.2158-2158

2019

Volltextzugriff (PDF)

Abstract 279A: Cell panel profiling of 162 small molecule therapeutics identifies response biomarkers for PARP, BET-family and proteasome inhibitors

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.279-279A

2019

Volltextzugriff (PDF)

Abstract A141: Computational models of synergy contribute to efficient combination screening

Molecular cancer therapeutics, 2019-12, Vol.18 (12_Supplement), p.A141-A141

2019

Volltextzugriff (PDF)

Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017

Molecular cancer therapeutics, 2019-02, Vol.18 (2), p.470-481

2019

Volltextzugriff (PDF)

Abstract 4907: Cell line panel profiling reveals novel drug response biomarkers for BTK and CDK4/6 inhibitors

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4907-4907

2018

Volltextzugriff (PDF)

Abstract 1944: High-throughput fluorescence-based assay for screening of Arginase I inhibitors for cancer immunotherapy

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.1944-1944

2018

Volltextzugriff (PDF)

Abstract 4185: NTRC 1501-0, a TTK kinase inhibitor selected for its long target residence time, completely inhibits tumor growth in the MDA-MB-231 xenograft model for triple-negative breast cancer

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.4185-4185

2017

Volltextzugriff (PDF)

1 – 25 von 191

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(138)
Mit Volltextzugriff
(180)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(84)
Life Sciences & Biomedicine
(57)
Humans
(49)
Biological And Medical Sciences
(27)
Animals
(22)
Medical Sciences
(19)
Female
(17)
Male
(17)
Middle Aged
(13)
Physical Sciences
(13)
Engineering
(12)
Science & Technology - Other Topics
(12)
Technology
(12)
Multidisciplinary Sciences
(11)
Mice
(10)
Mutation
(10)
Biochemistry & Molecular Biology
(9)
Cardiac & Cardiovascular Systems
(9)
Cardiovascular System & Cardiology
(9)
Computer Science
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Pharmacological validation of TDO as a target for Parkinson’s disease

TTK Inhibitors as a Targeted Therapy for CTNNB1 ( β -catenin) Mutant Cancers

Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use

A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets

Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combination

Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0

Structural insights into human Arginase-1 pH dependence and its inhibition by the small molecule inhibitor CB-1158

Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines

Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs

Optimisation of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors

An improved synthesis of 2-oxa-7-azaspiro[3,5]nonane and analogs as novel reagents in medicinal chemistry

Abstract 1480: Comparative cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020

Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity

Abstract B065: TTK inhibitors as a targeted therapy for β-catenin mutant cancers

Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance

LCK inhibition downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinoma

Abstract B060: Side-by-side comparison of small molecule IDO1 inhibitors in biochemical and cell-based assays and development of a IDO1 -expressing mouse model to evaluate target modulation

Preclinical evaluation of LCK as a novel therapeutic target in YAP-activated and FGFR2-altered cholangiocarcinoma

Abstract 2158: Combining cell panel profiling and synthetic lethality data to efficiently screen for synergistic combinations

Abstract 279A: Cell panel profiling of 162 small molecule therapeutics identifies response biomarkers for PARP, BET-family and proteasome inhibitors

Abstract A141: Computational models of synergy contribute to efficient combination screening

Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017

Abstract 4907: Cell line panel profiling reveals novel drug response biomarkers for BTK and CDK4/6 inhibitors

Abstract 1944: High-throughput fluorescence-based assay for screening of Arginase I inhibitors for cancer immunotherapy

Abstract 4185: NTRC 1501-0, a TTK kinase inhibitor selected for its long target residence time, completely inhibits tumor growth in the MDA-MB-231 xenograft model for triple-negative breast cancer

Suchergebnisse filtern